122 related articles for article (PubMed ID: 33391398)
1. The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis.
Lan T; Lu Y; Luo H; Yang O; He J; Xu H; Hu Z
J Cancer; 2021; 12(1):10-17. PubMed ID: 33391398
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
3. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
4. Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database.
Chen H; Yan L; Pu S; Zhu L; Zhang H; Zhou C
J Oncol; 2021; 2021():9988624. PubMed ID: 34580591
[TBL] [Abstract][Full Text] [Related]
5. The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis.
Xie Y; Du D; Song X; Li X; Ni Z; Huang H
World J Surg Oncol; 2022 Apr; 20(1):123. PubMed ID: 35430809
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
7. Research on the Role of Combined Chemotherapy and Radiotherapy in Patients With N+ Non-Metastatic Metaplastic Breast Carcinoma: A Competing Risk Analysis Model Based on the SEER database, 2000 to 2015.
Ma Y; Yang Z; Gao Y; Li K; Qiu P; Chen H; Pu S; Wang B; Zhou C
Front Oncol; 2020; 10():583488. PubMed ID: 33552959
[TBL] [Abstract][Full Text] [Related]
8. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
9. The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy.
Fu WF; Chen QX; Wang XX; Zhang J; Song CG
Front Oncol; 2020; 10():1753. PubMed ID: 33102205
[No Abstract] [Full Text] [Related]
10. Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database.
Zhang Y; Liu X; Ma M; Chen C; Wang X
Transl Cancer Res; 2023 Jul; 12(7):1741-1752. PubMed ID: 37588733
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis.
Janeva S; Zhang C; Kovács A; Parris TZ; Crozier JA; Pezzi CM; Linderholm B; Audisio RA; Olofsson Bagge R
Lancet Healthy Longev; 2020 Dec; 1(3):e117-e124. PubMed ID: 36094184
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
Zhang J; Wang W; Wang J; Luo Y; Chen S; Ma F; Xu B; Fan Y
J Oncol; 2020; 2020():8880727. PubMed ID: 33381180
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant chemotherapy in stage I-III male breast cancer: a SEER-based analysis.
Li WP; Gao HF; Ji F; Zhu T; Cheng MY; Yang M; Yang CQ; Zhang LL; Li JQ; Zhang JS; Wang K
Ther Adv Med Oncol; 2020; 12():1758835920958358. PubMed ID: 33014148
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Cancer Med; 2019 Feb; 8(2):554-563. PubMed ID: 30632300
[TBL] [Abstract][Full Text] [Related]
16. The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database.
Lan T; Lu Y; Zheng R; Shao X; Luo H; He J; Yang H; Xu H; Wang X; Hu Z
Front Oncol; 2021; 11():572230. PubMed ID: 33981594
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy for pT1-3N0-1 breast cancer patients with HR+, HER2- subtype: a propensity-score matched study with competing risk analysis.
Dong H; Su X; Li X; Fu P; Tan L
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12637-12646. PubMed ID: 37442867
[TBL] [Abstract][Full Text] [Related]
18. Research on the Role of Marriage Status Among Women Underwent Breast Reconstruction Following Mastectomy: A Competing Risk Analysis Model Based on the SEER Database, 1998-2015.
Zhang S; Yang Z; Qiu P; Li J; Zhou C
Front Surg; 2021; 8():803223. PubMed ID: 35127805
[TBL] [Abstract][Full Text] [Related]
19. Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database.
Wu Y; Qi Y; Yang J; Yang R; Lui W; Huang Y; Zhao X; Chen R; He T; Lu S; Wang Z; Li H; Sun X; Li Q; Zhou L; Chen J
J Evid Based Med; 2022 Dec; 15(4):354-364. PubMed ID: 36524240
[TBL] [Abstract][Full Text] [Related]
20. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis.
Wu C; Huang O; Wu J; Shen K; Chen X; Zhu S
Gland Surg; 2023 Oct; 12(10):1375-1386. PubMed ID: 38021197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
